Pharvaris N.V. (PHVS) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Schrodinger (SDGR) over the past year, gaining 41.2% versus a gain of 35.4%. Over five years, PHVS leads with a +100.5% price change compared with -50.7% for SDGR. Pharvaris N.V. is the larger company by market cap ($2.22 billion vs $2.04 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | SDGR |
|---|---|---|
| Share price | $31.68 | $27.29 |
| Market cap | $2.22B | $2.04B |
| 1-day change | +1.80% | -5.57% |
| YTD return | +14.16% | +52.63% |
| 1-year return | +41.18% | +35.37% |
| 5-year return | +100.51% | -50.70% |
| EPS (TTM) | $-3.06 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.25 | $33.78 |
| 52-week low | $20.65 | $10.95 |
| Distance from 52-week high | -26.75% | -19.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +80.62% | -21.47% |
| Average volume | 740.93K | 1.69M |
| Shares outstanding | 70.20M | 65.64M |
| Employees | 148 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
PHVS vs SDGR FAQ
Which is bigger, Pharvaris N.V. or Schrodinger?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.22B compared with $2.04B for Schrodinger (SDGR).
Which stock has performed better over the past year, PHVS or SDGR?
PHVS returned +41.18% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.